Elicio Therapeutics prices $15M registered direct offering of 4.38M shares at $3.43/share

Elicio Therapeutics, Inc.

Offering of 4,380,313 shares of common stock at $3.43 per share for gross proceeds of ~$15M.
Two new institutional investors and a large existing shareholder participated; expected close July 6, 2026.
Net proceeds to fund Phase 1 clinical development of ELI-002 7P in metastatic PDAC and pipeline/platform.
Titan Partners (lead) and B. Riley Securities (co-placement agent) acted as placement agents.
Offering made under effective shelf registration statement (File No. 333-293861).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.